P2X4 receptor has become an interesting molecular target for treatment and PET imaging of neuroinflammation and associated brain diseases such as Alzheimer's disease. This study reports the first design, synthesis, radiolabeling and biological evaluation of new candidate PET P2X4 receptor radioligands using 5-BDBD, a specific P2X4 receptor antagonist, as a scaffold. 5-(3-
Introduction
The purinergic P2X receptors are a family of cation-permeable ligand gated ion channels that open in response to the binding of extracellular adenosine 5'-triphosphate (ATP). 1 This ionotropic receptor family contains seven subunits P2X1-7. P2X receptors are involved in various physiological processes and associated with a variety of diseases including cancer, cardiovascular and neurological diseases. 2 P2X7 and P2X4 receptors are two predominant subtypes expressed on immune and neural cells. The over expression of P2X7 and P2X4
receptors is linked to neuroinflammation, which is an essential step in the progression of brain diseases. 3 Both P2X7 and P2X4 receptors have become a novel molecular target for treatment and PET (positron emission tomography) imaging of neuroinflammation and associated brain diseases such as Alzheimer's disease. 4 In our previous work, we have developed . 7 Here we report the design, synthesis, radiolabeling and preliminary biological evaluation of a series of radiolabeled 5-BDBD analogs as new candidate P2X4 receptor radioligands as shown in Figure 2 . (Figure 2 ).
Results and discussion

Chemistry
5-(3-Substituted phenyl)-1,3-dihydro-2H-benzofuro[3,2-e][1,4]diazepin-2-one analogs 5a-5f
were synthesized as outlined in Scheme 1. Starting from commercially available 2-hydroxybenzonitrile, it underwent alkylation with 3-substituted phenacyl bromides 1a-1f in the presence of Na 2 CO 3 in N,N-dimethylformamide (DMF) to obtain intermediate 2-(2-(3-substituted phenyl)-2-oxoethoxy)benzonotriles 2a-2f, which were cyclized with sodium methoxide in MeOH to provide (3-aminobenzofuran-2-yl)-(3-substituted phenyl)methanones 3a-3f in yields 82-98%. 10 As shown in Scheme 1, compound 1d was achieved by α-bromination of 3-iodoacetophenone with copper (II) bromide in EtOAc/CHCl 3 in 67% yield. 11, 12 Acylation of 6 amines 3a-3f with bromoacetyl bromide in the presence of NaHCO 3 in CHCl 3 afforded 2-bromo-N-(2-(3-substituted benzoyl)benzofuran-3-yl)acetamide 4a-4f in yields 75-89%. Treatment of 4a-4f with ammonia in dioxane for cyclization to give 5a-5f in yields 58-92%.
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Scheme 1. Synthesis of 5-BDBD analogs 5a-5f.
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Scheme 2. Synthesis of 5-BDBD analogs 6, 8c, 8f, 10 and 11.
As depicted in Scheme 2, desmethylation 14, 15 of 5f with BBr 3 in CH 2 Cl 2 afforded the precursor 5-
Methylation of 5c, 5f with CH 3 I in the presence of NaH in DMF gave N- isolated by HPLC-SPE to produce the corresponding radiolabeled product 5-(3-(2- 16 The radiosynthesis process included labeling reaction, purification and formulation. The overall synthesis, purification and formulation time was ~70 min from EOB.
The SA of [ 18 F]-tracer can be assessed by both semi-preparative HPLC (during synthesis) and analytical HPLC (EOS). 27 18 F-product SA was in a range of 111-740 GBq/µmol at EOB.
Chemical purity and radiochemical purity were determined by analytical HPLC. 27 The chemical purity of the precursors (6, 5c, 5e, and 10) and reference standards (9, 8c, 5a, and 11) was >90%.
The radiochemical purity of the target tracers ([ determined by radio-HPLC through γ-ray (PIN diode) flow detector, and the chemical purity of the target tracers was >90% determined by reversed-phase HPLC through UV flow detector.
In vitro binding studies
The preliminary biological evaluation of the carbon-11 radioligands [ 11 C]9 and [ 11 C]8c was performed by a radioligand depletion experiment. 6, 31 In this experiment, a wide range of protein was used for the optimization of the assay conditions. For the law of mass action to be valid, the protein and radioligand concentration need to be at levels where no more than 10% of the total radioligand added is bound to the protein. Otherwise the radioligand is considered depleted and specialized formulas for radioligand depletion must be used for analysis of the data in saturation or competitive binding assays. An optimized binding assay uses protein levels where the radioligand is depleted no more than 10%, and where sufficient signal to background binding levels, at least 5 fold total binding/non-specific binding ratio, are obtained. To achieve both of these ends, a wide range of membrane protein concentrations was tested to get the optimal level for the assay. The results indicated low affinity of 
Materials and methods
General
All commercial reagents and solvents were purchased from Sigma-Aldrich and Fisher Scientific, and used without further purification. 
2-Bromo-1-(3-iodophenyl)ethanone (1d)
To a stirred solution of 3-iodoacetophenone (5.0 g, 20.3 mmol) in EtOAc/CHCl 3 (100 mL/100 mL) was added CuBr 2 (9.1 g, 40.6 mmol). After the reaction mixture was heated under reflux for 3.5 h, it was cooled and filtered through Celite. The solvent was evaporated in vacuo to afford 1d as a white solid (4.4 g, 67%), which was used for next step without further purification. (1.33g, 12.6 mmol) in anhydrous DMF (15 mL) was stirred at room temperature (RT) overnight.
The reaction mixture was poured into water. The precipitate was collected by filtration and washed with water. The solid was dissolved in EtOAc, washed with brine, dried over anhydrous 
General procedure for preparation of compound 4
2-Bromo-N-(2-(3-fluorobenzoyl)benzofuran-3-yl)acetamide (4a
2-Bromo-N-(2-(3-chlorobenzoyl)benzofuran-3-yl)acetamide (4b
2-Bromo-N-(2-(3-bromobenzoyl)benzofuran-3-yl)acetamide (4c
2-Bromo-N-(2-(3-iodobenzoyl)benzofuran-3-yl)acetamide (4d
2-Bromo-N-(2-(3-nitrobenzoyl)benzofuran-3-yl)acetamide (4e
2-Bromo-N-(2-(3-methoxybenzoyl)benzofuran-3-yl)acetamide (4f
General procedure for preparation of compound 5
5-(3-Fluorophenyl)-1,3-dihydro-2H-benzofuro[3,2-e][1,4]diazepin-2-one (F-5-BDBD, 5a).
To a stirred compound 4a (1.0 g, 2.7 mmol) in dioxane (5 mL) was added ammonia (0.5 M solution in dioxane, 60 mL, 30.0 mmol). After the reaction mixture was stirred at RT for 2 days, EtOAc was added. The mixture was washed with water, brine, dried over anhydrous Na 2 SO 4 and filtered.
The solvent was evaporated in vacuo. 
5-(3-Chlorophenyl)-1,3-dihydro-2H-benzofuro[3,2-e][1,4]diazepin-2-one (5b). Compound 5b
was prepared with similar procedure as compound 5a from 4b. 
5-(3-Bromophenyl)-1,3-dihydro-2H-benzofuro[3,2-e][1,4]diazepin-2-one (5-BDBD, 5c).
Compound 5c was prepared with similar procedure as compound 5a from 4c. 402.9930. 
5-(3-Iodophenyl)-1,3-dihydro-2H-benzofuro[3,2-e][1,4]diazepin-2-one (5d
5-(3-Nitrophenyl)-1,3-dihydro-2H-benzofuro[3,2-e][1,4]diazepin-2-one (5e
5-(3-Methoxyphenyl)-1,3-dihydro-2H-benzofuro[3,2-e][1,4]diazepin-2-one (O-Me-5-BDBD, 5f).
Compound 5f was prepared with similar procedure as compound 5a from 4f. Yield: 75%, off white solid; mp 224-225 
5-(3-Hydroxyphenyl)-1,3-dihydro-2H-benzofuro[3,2-e][1,4]diazepin-2-one (6)
To a stirred suspension of compound 5f (1. 
tert-Butyl (3-(2-oxo-2,3-dihydro-1H-benzofuro[3,2-e][1,4]diazepin-5-yl)phenyl)carbonate (7)
A suspension of compound 6 (50 mg, 0.17 mmol), (Boc) 2 O (250 mg, 1.14 mmol) and DMAP (9 mg, 0.07 mmol) in CH 3 CN (2 mL) was stirred at RT for 2.5 h. 
General procedure for preparation of compound 8
5-(3-Bromophenyl)-1-methyl-1,3-dihydro-2H-benzofuro[3,2-e][1,4]diazepin-2-one (N-Me-5-BDBD, 8c).
To a stirred solution of compound 5c (200 mg, 0.56 mmol) in anhydrous DMF (2 mL) was added NaH (60% dispersion in mineral oil, 16 mg, 0.67 mmol). The reaction mixture was stirred at RT for 15 min, and methyl iodide (70 µL, 1.12 mmol) was then added. After the mixture was stirred at RT for 30 min, it was poured into ice-water and extracted with EtOAc.
The organic layer was washed with water, brine, dried over anhydrous Na 2 SO 4 and filtered. The solvent was evaporated in vacuo. The crude product was purified by preparative TLC plate using 369.0254.
5-(3-Methoxyphenyl)-1-methyl-1,3-dihydro-2H-benzofuro[3,2-e][1,4]diazepin-2-one (8f).
Compound 8f was prepared with similar procedure as compound 8c from 5f. Yield: 90%, pale yellow solid; mp 62-64 307.1070.
2-(3-(2-Oxo-2,3-dihydro-1H-benzofuro[3,2-e][1,4]diazepin-5-yl)phenoxy)ethyl 4-methylbenzenesulfonate (10)
To a stirred solution of compound 6 (200 mg, 0.7 mmol) in anhydrous DMF (4 mL) was added NaH (60% dispersion in mineral oil, 82 mg, 2.0 mmol) at 0 
5-(3-(2-Fluoroethoxy)phenyl)-1,3-dihydro-2H-benzofuro[3,2-e][1,4]diazepin-2-one (FE-5-BDBD, 11)
To a stirred solution of compound 6 (100 mg, 0.3 mmol) in anhydrous DMF (2 mL) was added NaH (60% dispersion in mineral oil, 41 mg, 1.0 mmol) at 0 
